FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate

FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate Additionally, the ExCel http://www.234btc.com/5880.html and IBIS-II trials reported that exemestane and anastrozole (respectively), significantly reduce invasive breast cancer in postmenopausal women who are at moderately increased risk for a new breast cancer (Cuzick et al., 2014). As the population of breast cancer survivors…